FDA to review STAAR toric ICL PMA
The FDA has given verbal notice indicating the agency’s intent to review STAAR Surgical Co.’s premarket approval (PMA) supplement regarding its toric ICL.
Monrovia, CA-The FDA has given verbal notice indicating the agency’s intent to review STAAR Surgical Co.’s premarket approval (PMA) supplement regarding its toric ICL.
The FDA will review the PMA at the Ophthalmic Devices Agency Panel meeting in February.
STAAR Surgical said it expects the federal register notice of the upcoming meeting to occur in early January.
Barry Caldwell, the company’s president and chief executive officer, gave a presentation to investors on the matter earlier this month.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
